ctDNA Clearance Predicts Relapse Risk in Urothelial Cancer

New research shows that ctDNA clearance following neoadjuvant treatment of muscle-invasive urothelial cancer can help predict response to therapy and the risk for relapse.

Related Keywords

London ,City Of ,United Kingdom ,Matthew Nicholas Young ,Barts Cancer Institute ,Nicholas Young ,Bladder Cancer ,Alignant Bladder Neoplasm ,Urothelial Cancer ,Neoadjuvant ,Cancer ,Alignant Neoplasia ,Arcinoma ,Alignant Neoplasm ,Biomarker ,Iological Marker ,Ulti Biomarker Disease Activity ,Bda ,Multibiomarker Disease Activity ,Muscles ,Pcr ,Polymerase Chain Reaction ,Cr Polymerase Chain Reaction ,Radical Cystectomy Of The Bladder ,Cystectomy ,Emoval Of Cyst ,Yst Removal ,Tumor ,